Valuation : Cytosorbents Corporation

Market Cap 21.09M 18.21M 17.07M 15.59M 29.33M 2.01B 29.46M 202M 79.01M 1.02B 79.18M 77.46M 3.38B P/E 2026 *
-1.53x
P/E 2027 * -7.46x
Enterprise Value 21.09M 18.21M 17.07M 15.59M 29.33M 2.01B 29.46M 202M 79.01M 1.02B 79.18M 77.46M 3.38B EV / Sales 2026 *
0.54x
EV / Sales 2027 * 0.48x
Free-Float
84.28%
Yield 2026 *
-
Yield 2027 * -
1 day-1.41%
1 week-9.30%
Current month-7.01%
1 month-5.20%
3 months-31.64%
6 months-55.40%
Current year-47.50%
1 week 0.32
Extreme 0.32
0.39
1 month 0.3
Extreme 0.3
0.4
Current year 0.3
Extreme 0.3
0.84
1 year 0.3
Extreme 0.3
1.04
3 years 0.3
Extreme 0.3
2.66
5 years 0.3
Extreme 0.3
9.8
10 years 0.3
Extreme 0.3
14.95
Manager TitleAgeSince
Chief Executive Officer 55 2008-07-23
Director of Finance/CFO 62 2024-08-13
President 68 2020-04-27
Director TitleAgeSince
Director/Board Member 77 2011-07-24
Director/Board Member 55 2008-12-31
Director/Board Member 65 2014-11-12
Date Insider Type Main position Quantity % Market Cap.
11/18/25 Free

Chief Executive Officer

100,000 0.1593%
8/8/25 Free

Chief Financial Officer

161,500 0.2579%
8/8/25 Free

Chief Executive Officer

242,000 0.3865%
Change 5-day change 1-year change 3-year change Capi.($)
-1.41%-9.30%-64.43%-86.41% 21.09M
-1.35%-1.13%+26.27%+12.02% 230B
+0.18%-1.27%+4.98%-18.16% 152B
+1.51%-1.64%-21.28%+20.04% 132B
+0.36%-7.01%-55.60%-14.34% 67.88B
+0.29%+0.47%+10.90%+15.91% 52B
+0.66%-1.69%-16.47%-14.35% 51.05B
-2.44%-3.25%+22.43%+26.08% 43.38B
-1.56%+0.97%+37.41%+44.08% 40.74B
+1.94%+3.81%-12.45%+46.61% 34.67B
Average -0.18%-1.69%-6.82%+3.15% 80.33B
Weighted average by Cap. -0.14%-1.29%+2.51%+7.85%

Financials

2026 *2027 *
Net sales 38.88M 33.58M 31.48M 28.73M 54.06M 3.71B 54.31M 373M 146M 1.88B 146M 143M 6.23B 44.16M 38.14M 35.75M 32.64M 61.41M 4.21B 61.69M 424M 165M 2.13B 166M 162M 7.07B
Net income -13.91M -12.01M -11.26M -10.28M -19.34M -1.33B -19.43M -133M -52.11M -671M -52.22M -51.09M -2.23B -2.77M -2.39M -2.24M -2.05M -3.85M -264M -3.87M -26.59M -10.38M -134M -10.41M -10.18M -444M
Net Debt - -
Logo Cytosorbents Corporation
CytoSorbents Corporation is engaged in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery through blood purification. The Company’s blood purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its lead product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses that can lead to massive inflammation, organ failure and patient death. Its products also include ECOS-300CY, VetResQ, DrugSorb-ATR, and PuriFi. DrugSorb-ATR is an investigational device that uses equivalent polymer technology to CytoSorb to address a large unmet need for blood thinner reversal in cardiothoracic surgery. ECOS-300CY is used to reduce cytokines and other inflammatory mediators when used in an ex vivo organ perfusion system.
Employees
129
Date Price Change Volume
26-08-28 $0.3356 -1.41% 113,684
26-08-27 $0.3404 -5.44% 108,592
26-08-26 $0.3600 +1.32% 26,283
26-08-25 $0.3553 -4.02% 123,629
26-08-24 $0.3702 +0.05% 158,191
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
0.3356USD
Average target price
2.375USD
Spread / Average Target
+607.69%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CTSO Stock